Andrew L. Niles is a Senior Research Scientist in Promega’s Advanced Technology Group. His scientific focus is directed at providing innovative solutions for improving in vitro gene editing efficiencies allowing for integration of bioluminescent tags and reporters. His work seeks to explore and detail how these approaches and methods are uniquely enabling for studying endogenous cell biology during drug target validation and discovery activities. His past research efforts have led to multiple “add-mix-measure” and real-time assay systems for evaluating cell health and/or assigning mechanism of cytotoxicity. He has authored several well-cited publications and reviews and has been granted 14 U.S. Patents. Promega Corporation is a global leader in providing innovative solutions and technical support to the life sciences industry, offering more than 4,000 products used in research, diagnostics, forensics and applied testing worldwide.